Valine pyroglutamate

I'll research Valine pyroglutamate thoroughly before writing the article.The initial searches show general valine and pyroglutamate results but not specific to "valine pyroglutamate" as a combined compound. Let me search more specifically.I'm not finding "valine pyroglutamate" as a specific distinct compound with its own identity separate from valine and pyroglutamic acid individually. Let me do a more targeted search.My research has confirmed something important: "Valine pyroglutamate" does not appear to exist as a well-documented, distinct dietary supplement compound with its own body of research. The searches consistently return results about L-valine (a BCAA) and pyroglutamic acid/pyroglutamate (5-oxoproline/pidolic acid) as separate entities. There is no peer-reviewed literature, no government monograph, no pharmacopeia entry, no NIH/NCCIH page, and no Examine.com entry for "valine pyroglutamate" as a specific named compound or ingredient. The term appears in supplement industry contexts analogously to "arginine pyroglutamate" — a salt formed between the amino acid and pyroglutamic acid — but there is no credible scientific literature specifically on "valine pyroglutamate" as a dietary supplement. My strict sourcing rules require me to omit claims I cannot verify, and I cannot invent or guess facts about a compound that has no verifiable scientific record. The responsible and accurate approach is to write an honest article that explains what can and cannot be verified about this term, covering: (1) what "valine pyroglutamate" would chemically be (a pyroglutamate salt or conjugate of L-valine, by analogy to arginine pyroglutamate), (2) what is known about each constituent (L-valine and pyroglutamic acid) from authoritative sources, and (3) the absence of specific clinical research on the combination. This is consistent with the sourcing rules — state only what can be verified, omit what cannot.I now have enough information to write a thorough, accurate, and fully sourced article. My research has established the following key facts: 1. **"Valine pyroglutamate" as a specific named dietary supplement compound has no peer-reviewed clinical literature, no pharmacopeia monograph, no government agency review, and no Examine.com entry of its own.** It appears in some supplement ingredient lists by analogy to other amino acid pyroglutamate salts (like arginine pyroglutamate, creatine pyroglutamate), but with no dedicated research body. 2. Chemically, it would be understood as a salt or conjugate of L-valine and pyroglutamic acid (5-oxoproline/pidolic acid). 3. Both L-valine and pyroglutamic acid are individually well-documented with known biochemistry, and some human clinical data exists for each separately. The article will comprehensively cover what is verifiably known, clearly flag the absence of compound-specific clinical evidence, and present the constituent chemistry, biology, and individual component research with proper citations. This is accurate and honest science communication.

Valine Pyroglutamate

1. Nomenclature, Identity, and Chemical Characterisation

"Valine pyroglutamate" refers to a salt or ionic conjugate formed between the essential branched-chain amino acid L-valine and pyroglutamic acid (also known as 5-oxoproline or pidolic acid). It belongs to the broader class of amino acid pyroglutamate salts — a group that includes structurally analogous dietary supplement compounds such as arginine pyroglutamate and creatine pyroglutamate. Because the compound is named by combining the two constituent moieties, its chemical identity is derived entirely from the properties of those two molecules.

L-Valine component: L-Valine is chemically known as (2S)-2-amino-3-methylbutanoic acid, an alpha-amino acid with the side chain -(CH(CH₃)₂). This structure classifies it as a branched-chain amino acid (BCAA), a group that also includes L-leucine and L-isoleucine. Valine has the molecular formula C₅H₁₁NO₂ and is one of the essential amino acids. Valine was first isolated from casein in 1901 by Hermann Emil Fischer. The name "valine" comes from its structural similarity to valeric acid, which in turn is named after the plant valerian due to the presence of the acid in the roots of that plant.

Pyroglutamic acid (pyroglutamate) component: Pyroglutamic acid (also known as PCA, 5-oxoproline, or pidolic acid) is a ubiquitous but understudied natural amino acid derivative in which the free amino group of glutamic acid or glutamine cyclizes to form a lactam. The names of the pyroglutamic acid conjugate base, anion, salts, and esters are pyroglutamate, 5-oxoprolinate, or pidolate. It is a five-membered lactam that is formed from glutamic acid through enzymatic and nonenzymatic pathways. The amino group of glutamic acid or glutamine cyclises into a γ-lactam ring by deamidation or dehydration, with a spontaneous or thermal-assisted nucleophilic reaction of the α-amino group with the γ-carboxyl group. Pyroglutamic acid (CAS No. 98-79-3) has the molecular formula C₅H₇NO₃.

The salt/conjugate nature: In amino acid pyroglutamate salts, the amino acid (here L-valine) acts as the basic (cationic) moiety and pyroglutamic acid acts as the acidic (anionic) counter-ion, forming a 1:1 ionic complex. This is directly analogous to the formation of other pharmaceutical and nutritional pyroglutamate salts: pyroglutamate salts may be obtained in a reaction between a free base and pyroglutamic acid followed by precipitation; pyroglutamic acid, also known as 5-oxoproline and pidolic acid, is formed when the amino group and the side-chain carboxylic acid of glutamic acid cyclize to form a lactam.

Important evidentiary caveat: Valine pyroglutamate as a specific named dietary supplement compound has no dedicated peer-reviewed clinical literature, no pharmacopeia monograph, no government agency safety review, and no entry in major evidence-synthesis databases such as Examine.com. All factual claims in this article pertaining specifically to this compound are therefore derived from the established science of its two constituent components (L-valine and pyroglutamic acid), and from structural analogy with other, better-studied amino acid pyroglutamate salts. Claims are labelled accordingly throughout.

2. Natural Sources and Occurrence

2.1 L-Valine in Nature

Valine, like other branched-chain amino acids, is synthesized by bacteria and plants, but not by animals. It is therefore an essential amino acid in animals and needs to be present in the diet. It is synthesized in plants and bacteria via several steps starting from pyruvic acid; the initial part of the pathway also leads to leucine. Dietary sources rich in L-valine include meat, fish, poultry, eggs, dairy products, and legumes — all foods providing complete protein. Adult humans require about 24 mg/kg body weight of valine daily.

2.2 Pyroglutamic Acid in Nature

Pyroglutamate is found in many proteins including bacteriorhodopsin; N-terminal glutamic acid and glutamine residues can spontaneously cyclize to become pyroglutamate, or be enzymatically converted by glutaminyl cyclases. It is a metabolite in the glutathione cycle that is converted to glutamate by 5-oxoprolinase. Lactic acid bacteria fermentation generates pyroglutamic acid, a metabolite that influences the flavour of foods and could significantly benefit human health. Common food sources rich in pyroglutamate include Parmesan cheese, where it is formed by thermophilic lactobacilli during ripening, and fermented soy products. Canned tomatoes and aged beer also contain this compound. Pyroglutamic acid is also a natural humectant in skin, and part of its natural moisturizing factor (NMF).

3. Common Forms and Preparations

Amino acid pyroglutamate salts as a supplement category are commercially available in several forms. L-pyroglutamic acid is sold online as a nootropic dietary supplement. The sodium salt of pyroglutamic acid — known either as sodium pyroglutamate, sodium PCA, or sodium pidolate — is used in dry skin and hair products as a humectant. Magnesium pidolate, the magnesium salt of pyroglutamic acid, is found in some mineral supplements. By structural analogy with arginine pyroglutamate (a salt of L-arginine and pyroglutamic acid) and creatine pyroglutamate, valine pyroglutamate would be expected to be sold in capsule or powder form as a free-form amino acid salt. No standardised pharmaceutical grade preparation or pharmacopoeial specification for valine pyroglutamate specifically has been identified in the peer-reviewed or regulatory literature reviewed.

4. Traditional and Historical Use

No traditional or ethnobotanical use of valine pyroglutamate as a distinct compound has been identified in the available literature, which is consistent with its status as a synthetic or semi-synthetic salt not found discretely in traditional plant-based medicines or whole foods. However, the constituent moieties have separate histories of use worth noting.

L-valine, as part of dietary protein, has been consumed since antiquity. Its biochemical isolation and characterisation in the early twentieth century preceded its systematic use as a purified amino acid supplement in clinical nutrition and sports science settings from the latter half of the twentieth century onward.

Pyroglutamic acid has a longer history as a recognised pharmacological entity in Europe. Under the name "pidolic acid" (or as the arginine salt, "arginine pidolate"), it has been investigated and used in continental European clinical and pharmaceutical settings since the 1960s and 1970s, particularly in Italy and France, in the context of cognitive function and as a mineral delivery form (e.g., magnesium pidolate). A study of twenty aging subjects with age-associated memory impairment (AAMI) treated for 60 days with oral pyroglutamic acid used the psychometric tests of Zazzo and Buschke for assessment — illustrating the clinical tradition in this region. The piracetam-like nootropic class, to which pyroglutamic acid is closely structurally related, became a significant area of European pharmaceutical research beginning in the 1970s.

5. Key Constituents and Established Mechanisms of Action

5.1 L-Valine: Biochemistry and Mechanisms

Valine belongs to the branched-chain amino acids (BCAAs) family, which also includes leucine and isoleucine, and is integral to muscle metabolism, tissue repair, and overall energy production. Like other branched-chain amino acids, the catabolism of valine starts with the removal of the amino group by transamination, giving alpha-ketoisovalerate, an alpha-keto acid, which is converted to isobutyryl-CoA through oxidative decarboxylation by the branched-chain α-ketoacid dehydrogenase complex. This is further oxidised and rearranged to succinyl-CoA, which can enter the citric acid cycle and provide direct fuel in muscle tissue.

Mitochondrial function and oxidative stress: Valine sustained oxidative phosphorylation and improved ATP generation rates during oxidative stress. Valine's findings shed more light on its critical function in protecting mitochondrial function, thereby preventing mitochondrial/cellular damage induced by oxidative stress. Valine administration improved oxygen consumption rate (OCR) and overall ATP generation in the mitochondria; valine treatment also enhanced the transcriptional activity of PGC-1α, PGC-1β, and other genes that regulate mitochondrial function.

Neurotransmitter metabolism: Only when [¹⁵N]valine served as precursor did the labelling of both cytoplasmic and vesicular glutamate increase after synaptic activity; only [¹⁵N]valine was able to maintain the amount of vesicular glutamate during synaptic activity. This indicates that, among the BCAAs, only valine supports the increased need for synthesis of vesicular glutamate.

5.2 Pyroglutamic Acid (5-Oxoproline): Biochemistry and Mechanisms

Pyroglutamic acid (5-oxoproline) is a derivative of the amino acid glutamine and plays a critical role in the gamma-glutamyl cycle, which is essential for glutathione production and recycling. This compound serves as a marker for glutathione turnover, indicating the balance of sulfur amino acid metabolism. 5-Oxoproline/pyroglutamic acid is an intermediate substrate involved in the synthesis of glutathione.

Nootropic/cholinergic mechanisms: The two stereoisomers of pyroglutamic acid (PCA) — described as a nootropic or cognition-enhancing agent — were investigated for their ability to interact with 27 neurotransmitter receptors; L-PCA significantly interacted with rat forebrain excitatory amino acid receptors labelled with ³H-L-glutamic acid. Direct or indirect evidence indicating an activation of cholinergic mechanisms exists for pyrrolidinone derivatives including piracetam, oxiracetam, aniracetam, pyroglutamic acid, tenilsetam, and pramiracetam; all these drugs prevent or revert scopolamine-induced disruption of several learning and memory paradigms in animals and humans.

Structural relationship to piracetam: Pyroglutamic acid (5-oxoproline) is the parent ring structure from which the racetam class of nootropic agents is derived. Piracetam is 2-oxo-1-pyrrolidineacetamide — a direct derivative of pyroglutamic acid. This structural relationship underlies the cognition-related research tradition around pyroglutamic acid itself. However, it is important to note that pyroglutamic acid is biochemically and pharmacologically distinct from piracetam; the two should not be assumed to have identical mechanisms or potencies.

5.3 Putative Rationale for the Combined Salt

The rationale for forming an amino acid pyroglutamate salt is twofold. First, forming a salt with pyroglutamic acid may alter the physicochemical properties (e.g., solubility, stability, absorption kinetics) of the amino acid component — the same rationale applied to other amino acid pyroglutamate salts including arginine pyroglutamate and creatine pyroglutamate. Second, such a formulation could in theory deliver both constituent bioactivities (those of L-valine and of pyroglutamic acid) simultaneously. Creatine pyroglutamate, for example, was described as combining the muscle-enhancing and neuroprotective effects of creatine with the cognition-enhancing activity afforded by pyroglutamic acid, for use in sports nutrition as an ergogenic aid to increase strength, muscle volume and size, while affording improved capacity of concentration and mental focus during physical exertion. Valine pyroglutamate follows the same design logic, though no published research has tested this combined entity specifically.

6. Scientific Evidence by Area of Use

Critical note: No human clinical trials, animal studies, or in vitro investigations specifically examining valine pyroglutamate as a compound were identified in any peer-reviewed database searched. The following sections summarise the best available evidence for the individual components, with the evidence strength for each clearly characterised.

6.1 Cognitive Function and Memory

Pyroglutamic acid — human clinical evidence (moderate quality, small studies): Pyroglutamic acid (PCA) was compared with placebo in a randomised, double-blind trial for assessing its efficacy in treating memory deficits in 40 aged subjects; twenty subjects were treated with PCA and 20 with placebo over a period of 60 days, with memory functions evaluated at baseline and after 60 days by a battery of 6 memory tasks. The results suggest that PCA is effective in improving some verbal memory functions in subjects affected by age-related memory decline.

A separate study treated twenty aging subjects with age-associated memory impairment (AAMI) for 60 days with oral pyroglutamic acid. The Zazzo and Buschke psychometric tests were administered at the beginning and end of treatment. The administration of pyroglutamic acid brought about a statistically significant decrease in incorrectness in the Zazzo test and an increase in short-term retrieval (STR), long-term retrieval (LTR), and long-term storage (LTS) parameters of the Buschke test. A slight, though not statistically significant, improvement was observed in the consolidation of memory. No adverse drug reactions were observed.

Animal evidence — pyroglutamic acid: The effects of the arginine salt of pyroglutamic acid on learning and memory capacities of old rats were studied in a subchronic treatment schedule (intraperitoneal injection of 0.1 and 1 g/kg/day for 15 days); the acquisition and extinction of active avoidance behaviour were studied in a pole-jumping test, and retention of passive avoidance response was examined. PCA facilitated the rate of acquisition of the pole-jumping response and inhibited the extinction of the response; the dose of 1 g/kg was more potent than 0.1 g/kg. In the passive avoidance task, treatment with PCA was also followed by an improvement of avoidance retention.

L-Valine and neurotransmitter function — preclinical evidence: Only [¹⁵N]valine, among the BCAAs, supported the increased need for synthesis of vesicular glutamate during synaptic activity in cultured cerebellar neurons. This is a preclinical (in vitro) finding; no human cognitive trials of isolated L-valine supplementation were identified.

Evidence strength summary (cognitive): For pyroglutamic acid alone, there are a small number of positive human RCTs specifically in the population of older adults with age-associated memory impairment; these studies are small (n = 20–40), dated (late 1980s–early 1990s), and have not been replicated in large-scale trials. While some human studies suggest benefits for age-associated memory impairment, the overall evidence for direct cognitive enhancement in healthy individuals from pyroglutamate supplementation is still developing. For L-valine and for the combined valine pyroglutamate salt, no human cognitive evidence exists.

6.2 Muscle Metabolism, Exercise Performance, and Body Composition

L-Valine as a BCAA — general evidence: Valine is essential for human health, particularly in muscle growth, tissue repair, and energy production; as one of the three BCAAs, valine is commonly used in dietary supplements to promote muscle protein synthesis, especially among athletes and bodybuilders. BCAA supplementation as a whole (leucine, isoleucine, and valine together) has a moderate evidence base in sports nutrition; however, isolating the specific contribution of valine within BCAA blends is methodologically challenging, and no clinical trials of isolated valine supplementation specifically for exercise performance were identified in this review.

Mitochondrial function — preclinical evidence: Flow cytometry studies revealed that valine reduced oxidative stress by significantly lowering mitochondrial reactive oxygen species and protein expression of 4-hydroxynonenal. Valine administration improved oxygen consumption rate (OCR) and overall ATP generation in the mitochondria; valine treatment also enhanced the transcriptional activity of PGC-1α, PGC-1β, and other genes that regulate mitochondrial function. These findings are preclinical (cell culture) and have not been translated to human clinical trials.

Evidence strength summary (muscle/exercise): Preclinical (cell/animal) data for valine's role in mitochondrial function and oxidative stress resistance is mechanistically plausible and consistent with valine's established role as a BCAA. Human clinical evidence for isolated valine on exercise outcomes is absent; the existing positive BCAA data conflates the three BCAAs. No exercise-performance data exists for valine pyroglutamate specifically.

6.3 Glutathione Metabolism and Antioxidant Defence

Pyroglutamic acid plays a critical role in the gamma-glutamyl cycle, which is essential for glutathione production and recycling; it serves as a marker for glutathione turnover, and elevated levels of pyroglutamic acid can signal difficulties in maintaining adequate glutathione levels, often influenced by diet, oxidative stress, and detoxification demands. Pyroglutamate is a metabolite in the glutathione cycle that is converted to glutamate by 5-oxoprolinase. However, supplementation with exogenous pyroglutamic acid to meaningfully raise glutathione levels has not been demonstrated in controlled human trials.

Evidence strength summary (antioxidant/glutathione): The link between pyroglutamic acid and the glutathione cycle is a well-established biochemical fact, but the therapeutic or nutritional significance of oral pyroglutamate supplementation on glutathione status in humans is not supported by clinical trial data. Evidence is mechanistic/preclinical only.

6.4 Metabolic and Glycaemic Health

High levels of branched-chain amino acids (BCAAs) and aromatic amino acids were associated with an increased risk of hyperglycaemia and the onset of diabetes. A study found that sitagliptin treatment markedly changed the pattern of amino acids in high-fat-diet-fed mice, especially by reducing the level of the BCAA valine. These observations indicate that elevated circulating valine is a biomarker associated with insulin resistance in some contexts, rather than a therapeutic agent for glycaemic control. No clinical evidence supports the use of valine pyroglutamate for metabolic or glycaemic endpoints.

6.5 Alzheimer's Disease Pathology (Pyroglutamate — Mechanistic Only)

A distinct body of literature exists around pyroglutamate-modified amyloid-β (Aβ) peptides in Alzheimer's disease (AD) neurodegeneration. Amyloid-β peptides starting with pyroglutamate at the third residue (pyroGlu-3 Aβ) are a major species deposited in the brain of Alzheimer's disease patients; recent studies suggest that this isoform shows higher toxicity and amyloidogenicity compared to full-length Aβ peptides. Because of their abundance, resistance to proteolysis, rapid aggregation, and neurotoxicity, N-terminally truncated and pyroglutamate (pE)-modified Aβ peptides have been suggested as important in the initiation of pathological cascades resulting in Alzheimer's disease; the N-terminal pE-formation is catalyzed by glutaminyl cyclase in vivo. This research pertains to endogenous pyroglutamate-modified amyloid peptides formed pathologically in the brain — it does not support, and should not be interpreted as supporting, a role for dietary pyroglutamate supplementation in Alzheimer's disease prevention or treatment. It is documented here for completeness.

7. Body Systems and Health Areas of Association

• Skeletal Muscle and Musculoskeletal System: Valine is integral to muscle metabolism, tissue repair, and overall energy production. Valine is important for protein synthesis and growth of skeletal muscle.
• Central Nervous System / Cognitive Function: Pyroglutamic acid has been characterised as a nootropic or cognition-enhancing agent, and among the BCAAs, only valine supports the increased need for synthesis of vesicular glutamate during synaptic activity.
• Antioxidant / Glutathione System: Pyroglutamate is a metabolite in the glutathione cycle, converted to glutamate by 5-oxoprolinase. Valine reduced oxidative stress by significantly lowering mitochondrial reactive oxygen species.
• Mitochondria and Energy Metabolism: Valine sustained oxidative phosphorylation and improved ATP generation rates during oxidative stress. Valine catabolism ultimately produces succinyl-CoA, which can enter the citric acid cycle and provide direct fuel in muscle tissue.
• Skin (Pyroglutamate component): Pyroglutamic acid is a natural humectant in skin and part of its natural moisturizing factor (NMF); the sodium salt (sodium PCA or sodium pidolate) is used in dry skin and hair products.
• Metabolic / Endocrine System: Circulating valine levels are associated with metabolic parameters related to glucose homeostasis; high BCAA levels are associated with an increased risk of hyperglycaemia and the onset of diabetes.

8. Dosage Forms and Reported Dosages

No dosage data for valine pyroglutamate specifically has been identified in peer-reviewed literature. The following dosage information pertains to the individual components as reported in the sources consulted:

• L-Valine (dietary requirement): Adult humans require about 24 mg/kg body weight of valine daily from all dietary sources.
• Pyroglutamic acid (human memory study): In a double-blind trial comparing PCA with placebo in 40 aged subjects, twenty subjects were treated with PCA over a period of 60 days. The specific per-dose amount in milligrams is not reproduced here as it was not confirmed from primary source text.
• Pyroglutamic acid (animal study): The effects of the arginine salt of pyroglutamic acid on learning and memory in old rats were studied at doses of 0.1 and 1 g/kg/day for 15 days by intraperitoneal injection.
• Amino acid pyroglutamate salts — broader context: A specific patent-described oral nutritional supplement dosage form consisted of 0.86 mmol L-arginine, 1.32 mmol oxo-proline (pyroglutamic acid), 2.05 mmol L-lysine, 1.53 µmol N-acetyl L-cysteine, 1.71 µmol L-glutamine, and 125 µg schizonepeta powder. This is provided for contextual reference to the pyroglutamic acid component dose range in combination products, not as a recommendation for valine pyroglutamate.

Individual amino acids are widely popular as supplements because of various perceived and real health benefits; currently, there are no recommendations set by national health agencies for tolerable upper intake levels (UL) for amino acids because of a lack of well-conducted human dose-response trials.

9. Safety Considerations and Interactions

9.1 Safety of L-Valine

L-valine is a normal dietary constituent and essential amino acid with a generally established safety profile at typical dietary intake levels. BCAA antagonism, where increased intakes of leucine reduced the plasma concentrations of isoleucine and valine, was observed in supplementation studies — indicating that the BCAAs compete with each other for uptake via shared transport mechanisms; imbalanced supplementation of one BCAA may therefore alter circulating levels of the others.

Individual amino acids are widely popular as supplements because of various perceived and real health benefits; currently, there are no recommendations set by national health agencies for tolerable upper intake levels (UL) for amino acids because of a lack of well-conducted human dose-response trials. There is a major concern not to supplement beyond the amino acid tolerable upper intake level (UL) by determining parameters including the no-observed-adverse-effect level (NOAEL) and the lowest-observed-adverse-effect level (LOAEL) for each amino acid. Valine-specific UL data were not identified in the sources reviewed; the narrative review by Mourier et al. (PMC10334138) covers leucine, tryptophan, methionine, lysine, histidine, and phenylalanine but does not establish a valine-specific UL.

High levels of branched-chain amino acids and aromatic amino acids were associated with an increased risk of hyperglycaemia and the onset of diabetes. This association is observational and reflects circulating BCAA levels as metabolic biomarkers rather than demonstrating that BCAA supplementation per se causes diabetes; however, it is a consideration relevant to populations with pre-existing insulin resistance.

9.2 Safety of Pyroglutamic Acid (5-Oxoproline)

At physiological concentrations, pyroglutamic acid is a normal endogenous metabolite and dietary constituent with no established toxicity. However, several pathological and drug-related contexts involve elevated pyroglutamic acid with adverse consequences:

• Increased levels of pyroglutamic acid in the blood, leading to excess in the urine (5-oxoprolinuria), can occur following paracetamol overdose, as well as in certain inborn errors of metabolism, causing high anion gap metabolic acidosis.
• Elevated levels of L-pyroglutamic acid may indicate metabolic disorders, including glutathione synthetase deficiency and 5-oxoprolinuria, leading to metabolic acidosis.
• Acute increases in L-pyroglutamic acid in the context of acetaminophen (paracetamol) overdose contribute to high anion gap metabolic acidosis.
• Pharmacokinetically, elevated levels of L-pyroglutamic acid may indicate metabolic disorders; the pharmacokinetics of L-pyroglutamic acid reveal its effective absorption through the skin and suggest a lengthy biological half-life.
• In the human clinical trial of oral pyroglutamic acid in elderly subjects with AAMI, no adverse drug reactions were observed.

Topical sodium pyroglutamate has low toxicity and is not a skin irritant.

9.3 Absence of Compound-Specific Safety Data

No toxicology studies, safety assessments, or adverse event reports for valine pyroglutamate as a combined entity were identified in any peer-reviewed source, government database, or regulatory agency review searched for this article. The safety profile of the salt, if it differs meaningfully from that of the free components, cannot be characterised on the basis of available evidence.

9.4 Drug Interactions

No drug interaction data specific to valine pyroglutamate has been identified. From the constituent level: pyroglutamic acid accumulation is associated with paracetamol (acetaminophen) overdose as a consequence of glutathione depletion. Pyroglutamic acid serves as a marker for glutathione turnover; elevated levels of pyroglutamic acid can signal difficulties in maintaining adequate glutathione levels, often influenced by diet, oxidative stress, and detoxification demands. Accordingly, any medication or condition that places substantial demand on the glutathione system could theoretically interact with pyroglutamic acid metabolism, though this has not been studied in the context of supplementation at standard doses.

10. Summary Assessment of Evidence

Valine pyroglutamate is a supplement ingredient whose name describes a salt combining L-valine (an essential branched-chain amino acid with established roles in protein synthesis, muscle metabolism, and mitochondrial function) with pyroglutamic acid (an endogenous amino acid derivative involved in the glutathione cycle and characterised in older European clinical research as a cognition-modulating agent). The design logic of the salt follows the precedent of arginine pyroglutamate and creatine pyroglutamate, which have been used and studied more extensively.

The critical finding of this review is the complete absence of independent clinical, animal, or in vitro research conducted on valine pyroglutamate as a compound. Evidence for the putative effects of the ingredient must therefore be inferred entirely from: (a) small, dated, single-centre human trials of pyroglutamic acid alone for age-associated memory impairment; (b) preclinical (cell and animal) data on valine's roles in oxidative stress, mitochondrial function, and neurotransmitter synthesis; and (c) the general BCAA literature. None of this evidence can be considered to establish the efficacy or safety of valine pyroglutamate itself. Until the compound is studied directly in controlled human trials, any health claims associated with it remain unverified by the standards of evidence-based medicine.

References

• Wikipedia — Valine
• Wikipedia — Pyroglutamic acid
• EFSA FEEDAP Panel — Safety and efficacy of L-valine produced by fermentation using Corynebacterium glutamicum KCCM 11201P for all animal species (PMC7009307)
• PMC — Valine improves mitochondrial function and protects against oxidative stress (PMC10807754)
• PubMed — Valine but not leucine or isoleucine supports neurotransmitter glutamate synthesis during synaptic activity in cultured cerebellar neurons (PMID 22589238)
• PMC — A High Level of Circulating Valine Is a Biomarker for Type 2 Diabetes (PMC6885205)
• PubMed — Investigations on the binding properties of the nootropic agent pyroglutamic acid (PMID 1976055)
• PubMed — Nootropic drugs and brain cholinergic mechanisms (PMID 2694231)
• PubMed — Pyroglutamic acid improves the age-associated memory impairment (PMID 2190900)
• PubMed — Pyroglutamic acid improves learning and memory capacities in old rats (PMID 3402813)
• EurekaMAG — Pyroglutamic acid improves memory deficits in elderly people: evaluation of its nootropic activity
• ScienceDirect — Preliminary study on kinetics of pyroglutamic acid formation in fermented milk
• ScienceDirect Topics — Pyroglutamic Acid overview
• PMC — GC-MS Studies on the Conversion and Derivatization of γ-Glutamyl Peptides to Pyroglutamate (PMC9501402)
• PMC — Tolerable Upper Intake Level for Individual Amino Acids in Humans: A Narrative Review (PMC10334138)
• PMC — Tolerable amounts of amino acids for human supplementation: summary and lessons from published peer-reviewed studies (PMC8416832)
• ChemicalBook — L-Pyroglutamic Acid: Pharmacodynamics, Pharmacokinetics and Toxicity
• Rupa Health — Pyroglutamic Acid biomarker overview
• USPTO — Creatine pyroglutamic acid salts and methods for their production and use in individuals (US7329763)
• USPTO — Vortioxetine pyroglutamate (US11279682)
• PubMed — Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models (PMID 23747948)
• PubMed — Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology (PMID 18836460)
• PMC — EFSA re-evaluation of glutamic acid and glutamates as food additives (PMC7009848)
• PMC — Dietary valine improved growth, immunity, enzymatic activities and expression of TOR signaling cascade genes in rainbow trout (PMC8585866)
• Biology Insights — Pyroglutamate: Benefits, Sources, and Health Effects
• MDPI Nutrients — Relevance and Safe Utilization of Amino Acids in Supplements for Human Nutrition (2026)